These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 32685378)
41. The origin of halitosis in cystinotic patients due to cysteamine treatment. Besouw M; Blom H; Tangerman A; de Graaf-Hess A; Levtchenko E Mol Genet Metab; 2007 Jul; 91(3):228-33. PubMed ID: 17513151 [TBL] [Abstract][Full Text] [Related]
42. The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire. van't Hoff WG; Gretz N Pediatr Nephrol; 1995 Dec; 9(6):685-9. PubMed ID: 8747105 [TBL] [Abstract][Full Text] [Related]
43. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis. Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217 [TBL] [Abstract][Full Text] [Related]
44. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate. Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073 [TBL] [Abstract][Full Text] [Related]
45. Pantethine and cystamine deplete cystine from cystinotic fibroblasts via efflux of cysteamine-cysteine mixed disulfide. Butler JD; Zatz M J Clin Invest; 1984 Aug; 74(2):411-6. PubMed ID: 6746900 [TBL] [Abstract][Full Text] [Related]
46. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326 [TBL] [Abstract][Full Text] [Related]
52. Cystine depletion by WR-1065 in cystinotic cells. Mechanism of action. Butler JD; Gahl WA; Tietze F Biochem Pharmacol; 1985 Jun; 34(12):2179-85. PubMed ID: 2988568 [TBL] [Abstract][Full Text] [Related]
53. Cysteamine prevents and reverses the inhibition of pyruvate kinase activity caused by cystine in rat heart. Rosa TG; de Souza Wyse AT; Wajner M; Wannmacher CM Biochim Biophys Acta; 2004 Jun; 1689(2):114-9. PubMed ID: 15196592 [TBL] [Abstract][Full Text] [Related]
54. Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. Ariceta G; Lara E; Camacho JA; Oppenheimer F; Vara J; Santos F; Muñoz MA; Cantarell C; Gil Calvo M; Romero R; Valenciano B; García-Nieto V; Sanahuja MJ; Crespo J; Justa ML; Urisarri A; Bedoya R; Bueno A; Daza A; Bravo J; Llamas F; Jiménez Del Cerro LA Nephrol Dial Transplant; 2015 Mar; 30(3):475-80. PubMed ID: 25348508 [TBL] [Abstract][Full Text] [Related]
55. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome. Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193 [TBL] [Abstract][Full Text] [Related]
56. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. Thoene JG; Oshima RG; Crawhall JC; Olson DL; Schneider JA J Clin Invest; 1976 Jul; 58(1):180-9. PubMed ID: 932205 [TBL] [Abstract][Full Text] [Related]